PLEASANTON, Calif., July 26 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in products to treat cardiovascular disease, today announced that it will report its operating results for the second quarter of fiscal 2007 on Tuesday, July 31.
The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 8:30 a.m., Pacific Daylight Time (11:30 a.m., Eastern Daylight Time), Tuesday, July 31, hosted by Gary F. Burbach, president and chief executive officer, and David Smith, executive vice president and chief financial officer.
The teleconference can be accessed by calling (913) 981-4911, passcode 9051445. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available on the Internet at http://phx.corporate-ir.net/phoenix.zhtml?p=iroleventDetails&c=95989&eventID= 1600142 or at http://www.thoratec.com.
A replay of the conference call will be available through Tuesday, August 14, via http://www.thoratec.com or by telephone at (719) 457-0820, passcode 9051445.
Thoratec Corporation is a world leader in therapies to address advanced stage heart failure. The company’s product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 11,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web sites at http:///www.thoratec.com or http://www.itcmed.com
Thoratec Corporation
CONTACT: David Smith, Executive Vice President, Chief Financial Officer ofThoratec Corporation, +1-925-847-8600; or Neal Rosen of the Kalt RosenGroup/Ruder Finn, +1-415-692-3058, for Thoratec Corporation
Web site: http://www.thoratec.com/
